ACRS Q1 2024 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$435M

Q1 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$2M-5.1% YoY

Gross Profit

$558,00023.3% margin

Operating Income

-$19M-789.4% margin

Net Income

-$17M-706.5% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

-86.4%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$174M

Total Liabilities

$32M

Stockholders' Equity

$142M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$3M	-5.1%
Gross Profit	$558,000	$659,000	-15.3%
Operating Income	-$19M	-$30M	+36.7%
Net Income	-$17M	-$28M	+39.8%

Revenue Segments

License and Service

$2M73%

Contract research

$657,00027%